Indivior plc Stock
€12.10
Your prediction
Indivior plc Stock
Pros and Cons of Indivior plc in the next few years
Pros
Cons
Performance of Indivior plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Indivior plc | -1.650% | 0.000% | 22.222% | -22.930% | 1.681% | -29.855% | 234.254% |
| Hikma Pharmaceuticals | -1.600% | -1.600% | 3.361% | 4.237% | 3.361% | 31.551% | -5.385% |
| Viatris Inc. | 0.200% | 4.148% | 0.487% | -20.964% | -34.029% | -26.469% | -45.680% |
| Opko Health Inc. | -1.970% | -0.618% | 6.107% | -2.965% | -18.949% | -55.782% | -51.401% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Indivior, a company in the pharmaceuticals sector, offers an interesting glimpse into its current standing and potential trajectory. With a market capitalization just over $1.63 billion, the firm operates within a challenging industry, marked by innovations and regulatory hurdles. As the financial landscape continuously shifts, this analysis provides a nuanced look at both the strengths and weaknesses evident in Indivior's financial data.
Beginning with the pros, several positive indicators emerge from Indivior’s financial ratios. The reported revenue stands at approximately $1.15 billion, complemented by a Gross Profit of around $742 million, shining a light on the company’s ability to generate sales. This is particularly significant when considering the quarterly revenue growth year over year, which is reported at 8.3%. Such growth can indicate increasing demand for the company’s products and a healthy trajectory in terms of market competitiveness.
Furthermore, the Return on Assets (ROA) is relatively stable at 2.37%, suggesting that the company is somewhat effective in utilizing its assets to generate profits. In the same vein, the Return on Equity (ROE) shows a robust figure of 12.2%, reflecting that shareholders are earning a reasonable return on their investments, despite the challenges the company faces in a rapidly-evolving pharmaceutical market.